MedinCell provides an update on its product portfolio, following the FDA Acceptance of New Drug Application for the product mdc-IRM September 1, 2021 September 1, 2021
Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia August 31, 2021 August 31, 2021
MedinCell announces the availability of its 2020/2021 Universal Registration Document including the Annual Financial Report July 28, 2021 July 28, 2021
MedinCell announces fiscal year consolidated results April 2020 – March 2021 June 16, 2021 June 16, 2021
MedinCell’s Long-Acting Injectable to fight Malaria ready to enter Regulatory Development June 14, 2021 June 14, 2021
Videoconference and publication of the results for the 2020-2021 financial year, on June 16, 2021 June 1, 2021 June 1, 2021
Clinical trial conducted by MedinCell confirms the safety of continuous administration of ivermectin April 19, 2021 April 19, 2021
Covid-19: MedinCell publishes an extensive Ivermectin Safety Expert Analysis March 5, 2021 March 5, 2021
Tremendous success for MedinCell’s €30 million capital increase for qualified investors February 11, 2021 February 11, 2021
